OncoMatch/Clinical Trials/NCT04834024
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Is NCT04834024 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide and lenalinomide for follicular lymphoma and marginal zone lymphoma.
Treatment: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide · lenalinomide — This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 CD20-positive
histologically documented CD20-positive FL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody (rituximab)
Evidence of refractory to rituximab
Cannot have received: immunomodulatory agent (lenalidomide)
Evidence of refractory to lenalinomide
Cannot have received: antibody therapy
Exception: except for Rituximab
Prior use of any antibody therapy(except for Rituximab ) within 3 months of study start
Cannot have received: anti-cancer vaccine
Prior use of any anti-cancer vaccine
Cannot have received: radiotherapy
Prior administration of radiotherapy 42 days prior to study entry
Cannot have received: chemotherapy
Prior administration of chemotherapy 28 days prior to study entry
Lab requirements
Blood counts
adequate hematologic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify